Company news

Esperion Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ESPERION Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Company Update

February 22, 2021

Esperion to Report Fourth Quarter and Full Year 2020 Financial Results February 23, 2021

February 8, 2021

ESPERION Reports Preliminary Fourth Quarter 2020 Financial Results and Further Commits to Unmet Patient Needs with Oral PCSK9 Inhibitor Program

January 12, 2021

ESPERION Appoints Sheldon Koenig as Chief Operating Officer

December 14, 2020

Esperion Announces Pricing of Offering of $250.0 Million of Convertible Senior Subordinated Notes

November 11, 2020

Esperion Announces Private Offering of $200.0 Million of Convertible Senior Subordinated Notes

November 9, 2020

ESPERION Reports Third Quarter 2020 Financial Results and Provides Company Update

November 1, 2020

Esperion to Report Third Quarter 2020 Financial Results November 2, 2020

October 18, 2020

Esperion Launches U.S. Direct-to-Consumer Campaign to Accelerate Awareness of NEXLETOL® (bempedoic acid) Tablets and Increase Awareness of Bad Cholesterol

September 27, 2020

Esperion Announces Two Data Presentations of NEXLETOL® (bempedoic acid) Tablet at the ESC Congress 2020

August 25, 2020

Esperion Reports Second Quarter 2020 Financial Results and Provides Company Update

August 9, 2020

Esperion to Report Second Quarter 2020 Financial Results August 10, 2020

August 2, 2020

Esperion Announces Publication in the Journal of the American Medical Association Cardiology of Pooled Efficacy Analysis from the Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL® (bempedoic acid) Tablets

June 30, 2020

Esperion and Daiichi Sankyo Europe Announce Amendment to License and Commercial Collaboration Agreement

June 21, 2020

Esperion Announces Pooled Analysis from Phase 3 LDL-C Lowering Clinical Development Program of NEXLETOL™ (Bempedoic Acid) Tablets Presented at the American Diabetes Association 80th Scientific Sessions

June 13, 2020

Esperion Announces Commercial Availability of NEXLIZET™ (bempedoic acid and ezetimibe) Tablets and Ushers in New Era of Oral Combination Medicine for LDL-Cholesterol Lowering

June 3, 2020

Esperion Reports First Quarter 2020 Financial Results and Provides Company Update

May 5, 2020

Esperion to Report First Quarter 2020 Financial Results May 6, 2020

April 29, 2020

Esperion Announces Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of NEXLETOL™ (bempedoic acid) and NEXLIZET™ (bempedoic acid and ezetimibe) Tablets in Japan

April 19, 2020

Esperion Announces European Commission Approval of the NUSTENDI™ (bempedoic acid and ezetimibe) Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

April 5, 2020

Esperion Announces Commercial Availability of the NEXLETOL™ (bempedoic acid) Tablet and Pledges a Conscientious Launch During Unprecedented Moment in Healthcare

March 29, 2020

Esperion Announces the Appointment of Alan Fuhrman to its Board of Directors

March 17, 2020

Esperion Announces FDA Approval of the NEXLIZET™ (bempedoic acid and ezetimibe) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

February 25, 2020

Esperion Announces FDA Approval of NEXLETOL™ (bempedoic acid) Tablet, an Oral, Once-Daily, Non-Statin LDL-Cholesterol Lowering Medicine

February 20, 2020

Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for the Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia

January 30, 2020

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Clinical Development Program of Bempedoic Acid Presented at the American Heart Association 2019 Scientific Sessions

November 16, 2019

Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results

November 11, 2019

Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results

November 5, 2019

Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions

November 3, 2019

Esperion to Report Third Quarter 2019 Financial Results November 6, 2019

October 28, 2019

Esperion Announces Publication in The Journal of the American Heart Association of Bempedoic Acid Study 3 Results

March 31, 2019

← Newer news releases

Calls

The 5 newest of 21 calls. Every call is listed under its year.

Decks

The 5 newest of 7 decks. Every deck is listed under its year.